DATE: May 6, 2011

TO: CIBMTR Data Managers and Medical Directors

FROM: J. Douglas Rizzo, MD MS

RE: Forms Required for HRSA Reporting Requirements

As part of the Stem Cell Therapeutic Outcomes Database (SCTOD) contract, the CIBMTR has certain reporting requirements established by HRSA. This is often referred to as Transplant Essential Data reporting and these data are the foundation of the TED Follow-up track. For allogeneic HCT recipients, Essential Data includes those data collected on the following forms:

- Form 2400: Pre-TED 2400
- Form 2004: Infectious Disease Markers – for non-NMDP Cord Blood HCT
- Form 2005: HLA Typing – for non-NMDP Cord Blood HCT
- Form 2006: Infusion Form – for all NMDP facilitated HCT, and all cord blood HCT
- Form 2450: Post-TED
- Form 2451: Chimerism Studies – for Cord Blood Cases assigned to TED follow-up track; these data are needed by Cord Blood Banks for their regulatory reporting requirements.

It has recently come to the attention of CIBMTR that some of these forms were not being made due by the FormsNet application’s automatic rules, especially in the cases where the recipient declined to participate in research. If the patient has declined to participate in research activities, these data will only be used to satisfy CIBMTR’s reporting needs and not for any research studies.

The CIBMTR is currently in the process of adding these forms to your forms due lists when appropriate. Because the timing of these additions coincided with the end of the April CPI period, CIBMTR will be closely reviewing the CPI status for each center. If the addition of these forms has caused a center to not make CPI, this center will not be held accountable for the forms until the following CPI period (closed August 31, 2011).

If you have any questions or concerns regarding the above, please contact your liaison for follow-up.